|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1519.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 36,851.70 | 39,050.80 | 33,506.60 | 29,643.10 | 24,928.30 | Adjustment | 2,695.70 | 732.60 | 5,204.10 | -357.30 | 1,876.00 | Changes In working Capital | 1,645.70 | -2,708.80 | 5,411.90 | -2,454.60 | -7,610.00 | Cash Flow after changes in Working Capital | 41,193.10 | 37,074.60 | 44,122.60 | 26,831.20 | 19,194.30 | Cash Flow from Operating Activities | 30,350.50 | 27,734.30 | 34,603.10 | 20,181.40 | 14,680.50 | Cash Flow from Investing Activities | -27,579.50 | -24,637.30 | -33,604.50 | -11,263.30 | -11,470.50 | Cash Flow from Financing Activities | -4,247.70 | -4,267.20 | -658.00 | -6,938.90 | -4,733.20 | Net Cash Inflow / Outflow | -1,476.70 | -1,170.20 | 340.60 | 1,979.20 | -1,523.20 | Opening Cash & Cash Equivalents | 1,772.90 | 2,947.20 | 2,615.40 | 644.70 | 2,174.50 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | -1.40 | -4.10 | -8.80 | -8.50 | -6.60 | Closing Cash & Cash Equivalent | 294.80 | 1,772.90 | 2,947.20 | 2,615.40 | 644.70 |
|
|
|
|
|
|